Scientists from Department of Atomic Energy and IDRS Labs Pvt. Ltd. Bengaluru have joined hands to develop AKTOCYTE tablets.
- Experts from these institutes collaborated with a primary aim of minimizing the side effects of radiotherapy.
- The AKTOCYTE tablets have shown remarkable results, particularly in pelvic cancer patients suffering from radiotherapy-induced Cystitis (Blood in urine).
- AKTOCYTE is positioned as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant, showcasing its versatility in cancer care.
- AKTOCYTE has received approval from the Food Safety and Standards Authority of India (FSSAI), operating under the Ministry of Health & Family Welfare, Government of India.
